{"title": "PDF", "author": "PDF", "url": "https://hsc.unm.edu/echo/_docs/hhs-covid/hhs-miniseries/limbago.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Brandi Limbago, Ph.D. presenting for Vivien Dugan, Ph.D. and the Surveillance and Emerging Variants Team CDC COVID -19 Emergency Response March 24, 2021Variant Classifications Established in collaboration with the SARS -CoV-2 Interagency Group (SIG) -Each variant class includes possible attributes of lower classes; variant status might escalate or deescalate based on scientific evidence Variant of Interest : contains specific genetic markers associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, reduced efficacy of treatments, potential diagnostic impact, or predicted increase in transmissibility or disease severity Variant of Concern : evidence of an increase in transmissibility, more severe disease (hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures Variant of High Consequence : clear evidence that prevention measures or medical countermeasures (MCMs) have significantly reduced effectiveness relative to previously circulating variants SARS -CoV -2 Variants of Concern | transmission5 Likely increased severity based on hospitalizations and case fatality rates Minimal impact on neutralization by EUA monoclonal antibody therapeutics Minimal impact on impact on neutralization by EUA monoclonal antibody therapeutics Moderate reduction on neutralization by some, but not all, EUA therapeutics Moderate reduction in neutralization neutralization by some, but not all, EUA therapeutics Moderate reduction in neutralization using convalescent and post -vaccination sera SARS -CoV -updates/variant -info.htmlNational SARS -CoV-2 Variant NS3 and CDC contracts >25,000 sequences; are increasing B.1.351 P .1 VOCs remain well below 0.5%.Rolling 12 -week Period Four February 27, 2021 https://www.cdc.gov/coronavirus/2019 -ncov/cases -updates/variant -proportions.htmlCOVID -19 IM Meeting Slide Submission Template Y 5 Expect these data will change Variant Proportions in the U.S. | CDC page - CDC sequence data: NS3 and contract laboratories - Four weeks ending February 13, 2021 VOC proportion estimates shown for states meeting threshold of 300 sequences from specimens collected during timeframe - 19 states - B.1.1.7, B.1.351, P .1, B.1.427, B.1.429 USG chose to use a threshold of 20% prevalence of L452R to guide distribution of bamlanivimab - This action will only affect the states of California, Arizona and Nevada at this time Currently, CDC notrequesting B.1.427/429 variants be reported -updates/variant -proportions.html FDA authorizes revisions fact sheets to address SARS -CoV-2 variants for monoclonal antibody products under emergency use authorization | FDACMS CLIA SARS -CoV-2 Testing FAQ Issued March 10, 2021; modified March 19 Enforcement discretion for public health reporting of variants CLIA SARS -CoV-2 Variant Testing Frequently Asked Question -Updated 03.19.2021 (cms.gov) -https://www.cms.gov/files/document/clia -sars-cov-2-variant.pdf More guidance expected per CMS For more information, contact CDC 1-800-CDC-INFO (232 -4636) TTY: 1 -888-232-6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Variants of Interest Name (Pango lineage) SubstitutionName in neutralization by monoclonal antibody treatments Potential reduction in neutralization by convalescent and in neutralization by monoclonal antibody treatments Potential reduction in neutralization by convalescent reduction in neutralization by monoclonal antibody treatments Potential reduction in neutralization by convalescent and post -vaccination sera SARS -CoV "}